Recent studies have found that GLP-1 drugs, initially developed for diabetes treatment and weight loss, may substantially lower mortality rates in the U.S. by 2045, according to research from Swiss Re, a reinsurance company in Zurich, Switzerland. The findings indicate a potential 6.4% reduction in all-cause mortality for Americans over the next two decades.
Researchers highlighted that obesity, which contributes to 70% of leading death causes in high-income nations such as the U.S. and U.K., plays a key role in stalling progress in life expectancy. With more than 40% of U.S. adults classified as obese, the nation faces a significant health crisis. Additionally, the U.K. also has a high obesity rate, with around 30% of its population affected.
Swiss Re’s analysis suggests that the widespread adoption of GLP-1 drugs, which are already showing promising results in reducing the risks of conditions like heart disease, stroke, and cancer, could contribute significantly to improving national health outcomes. The researchers emphasized the importance of combining medication with lifestyle changes, such as diet and exercise, to ensure long-term success.
According to Paul Murray, CEO of Life & Health Reinsurance at Swiss Re, the potential impact of these drugs is substantial, particularly in the context of the growing obesity epidemic. He noted that while the drugs offer significant promise, the full benefits will only be realized if they are paired with broader efforts to promote health and prevent disease. This includes the role of insurers in supporting policy initiatives and encouraging sustainable lifestyle shifts.
Furthermore, experts like Dr. Sue Decotiis, a triple board-certified weight loss physician, have confirmed that GLP-1 medications can improve a range of conditions beyond weight loss and diabetes, including heart, kidney, liver, and skin conditions, as well as cognitive decline and certain cancers. This broader application highlights the potential of these drugs to address multiple health challenges simultaneously.
However, without a commitment to dietary and lifestyle changes, the benefits of these medications may be limited, as studies show that weight regain and rebound effects are common if individuals do not maintain sustainable habits. The researchers stress that medication alone is not enough, and the integration of holistic health strategies is essential for long-term success.
As the use of GLP-1 drugs becomes more prevalent, the focus will likely shift towards understanding their broader impacts on public health, including how they interact with existing healthcare systems and what long-term data will reveal about their effectiveness in reducing mortality and improving quality of life.